Lipidation and half-life extension
Native peptides are cleared from circulation quickly. This guide explains the main strategies used to extend their persistence: fatty acid side chains and albumin binding, PEGylation, Fc fusion and albumin fusion, and the Drug Affinity Complex approach.
Why native peptides are short-lived
Many endogenous peptides act briefly by design. Hormones such as GLP-1 and growth hormone-releasing hormone are cleaved by circulating and membrane-bound proteases and, being small, are filtered rapidly by the kidney. In pharmacology this is a challenge, because a molecule that disappears within minutes is hard to study or develop as a medicine.
Two broad problems are addressed by half-life extension. The first is enzymatic degradation, which is tackled by substituting residues at cleavage sites, for example with Aib or D-amino acids, or by cyclization. The second is renal filtration, which is tackled by making the molecule effectively larger, either by attaching it to a large carrier or by giving it a way to bind one reversibly. Most successful long-acting peptides combine both approaches.
Fatty acid side chains and albumin binding
Lipidation attaches a fatty acid, usually through a lysine side chain and often via a hydrophilic linker, to the peptide. Serum albumin, the most abundant plasma protein, has binding sites that naturally carry fatty acids. A lipidated peptide binds albumin reversibly, so most of it circulates in a bound form that is too large to be filtered by the kidney and is partly shielded from proteases. Only the unbound fraction is free to reach receptors at any moment.
Lipidated peptides also self-associate. Many form oligomers or micelle-like assemblies at the injection site and in formulation, which slows absorption and contributes to prolonged exposure. The choice of fatty acid length, the use of a diacid rather than a monoacid, the linker composition and the attachment position all tune albumin affinity and receptor potency.
- Liraglutide: a GLP-1 analogue with a C16 palmitoyl group attached through a glutamate spacer.
- Semaglutide: a C18 fatty diacid attached through a hydrophilic linker, combined with an Aib substitution that resists DPP-4 cleavage.
- Tirzepatide: a dual GIP and GLP-1 receptor agonist with a C20 fatty diacid side chain.
- Insulin detemir and insulin degludec: lipidated insulins that apply the same principle.
PEGylation
PEGylation attaches one or more chains of polyethylene glycol (PEG), a flexible, highly hydrated polymer, to the peptide. The PEG greatly increases the hydrodynamic size of the molecule, reducing renal filtration, and can hinder access by proteases and antibodies. PEG chains are polydisperse, so a PEGylated peptide is a distribution of masses rather than a single species, which complicates analysis.
Attachment chemistry matters. PEG is commonly coupled to lysine amines, the N-terminus or an engineered cysteine, and the site affects how much receptor activity is retained. Large PEG chains can reduce potency, and antibodies against PEG have been reported in some people, which is an active area of study. PEG-MGF is a research example in which a fragment of mechano growth factor is PEGylated; it is not an approved drug and its characterization depends heavily on the PEG reagent used.
Fc fusion and albumin fusion
A different strategy fuses the peptide genetically to a large protein that the body recycles. The Fc region of immunoglobulin G binds the neonatal Fc receptor (FcRn), which rescues it from lysosomal degradation and returns it to circulation, giving IgG its long persistence. Fusing a peptide to an Fc domain confers some of this recycling behavior and adds substantial size. Dulaglutide, a GLP-1 analogue fused to a modified IgG4 Fc, is an approved example.
Albumin itself is also recycled through FcRn, and peptides have been fused directly to albumin, as in albiglutide, a GLP-1 receptor agonist that was approved and later withdrawn from the market for commercial reasons. Fusion proteins are made recombinantly, so their impurity profile and analytical requirements are those of biologics rather than synthetic peptides.
Drug Affinity Complex (DAC)
Drug Affinity Complex, or DAC, is a technology in which a peptide carries a reactive maleimide group, usually on an added lysine near the C-terminus. The maleimide is designed to react with the free thiol of cysteine-34 on circulating albumin, forming a covalent conjugate after administration rather than a reversible complex.
CJC-1295 is the best-known example in the research literature. The name is used for two different materials: the DAC version, carrying the maleimide-modified lysine, and a version without DAC, which is a tetra-substituted GHRH(1-29) analogue sometimes called modified GRF(1-29). These are distinct molecules with different masses and should not be confused; a certificate of analysis should make clear which one is present. Maleimide groups can hydrolyze in solution, which is an additional stability consideration.
Analytical considerations
Half-life-extended peptides present analytical challenges beyond those of simple sequences. Lipidated peptides are strongly retained in reversed-phase HPLC, may need modified gradients or column chemistries, and can aggregate during analysis. Their masses must include the full linker and fatty acid, so identity should be checked against the complete structure rather than the peptide backbone alone.
PEGylated material gives a broad mass distribution centered on the average PEG size and requires methods such as MALDI-TOF or charge-reduced ESI to characterize. Free PEG, unconjugated peptide and multiply PEGylated species are relevant impurities. For DAC peptides, the maleimide-bearing and hydrolyzed forms differ by 18 Da. See HPLC and mass spec explained.
Interpreting research on modified peptides
A modified peptide is a different molecule from its parent. Its receptor potency, distribution, clearance and safety profile have to be established for that molecule specifically, and findings for one analogue cannot be transferred to another simply because they share a backbone. This applies to approved drugs as much as to research compounds.
When reading literature, check exactly which version was studied, including the linker, fatty acid, PEG size or fusion partner, and whether the work was in vitro, in animals or in human trials. On this wiki, each compound page states its highest level of human evidence. The guide on how to read preclinical research discusses why exposure in animal models does not translate directly to people.
Frequently asked questions
How does a fatty acid side chain extend a peptide's half-life?
The fatty acid allows the peptide to bind serum albumin reversibly. Bound peptide is too large for renal filtration and partly protected from proteases, so it circulates much longer than the native peptide. Self-association into oligomers at the site of administration can also slow absorption. Lipidation is usually combined with substitutions that resist enzymatic cleavage.
What is the difference between CJC-1295 with DAC and without DAC?
Both are modified GHRH(1-29) analogues. The DAC version carries an extra lysine bearing a maleimide group designed to bond covalently to albumin, while the version without DAC lacks that group and is sometimes called modified GRF(1-29). They have different structures and masses, so documentation should state clearly which molecule is supplied.
Is PEGylation the same as lipidation?
No. PEGylation attaches a large, water-soluble polymer that increases the molecule's size directly. Lipidation attaches a small fatty acid that works by binding albumin reversibly. They extend persistence through different mechanisms and create different analytical challenges, with PEGylated peptides showing a distribution of masses.
Compounds mentioned
Cite this page